Skip to main content
Top
Published in: Clinical and Experimental Nephrology 6/2019

01-06-2019 | Erythropoietin | Original article

Regional variance in patterns of prescriptions for chronic kidney disease in Japan

Authors: Reiko Inoue, Hiroshi Nishi, Tetsuhiro Tanaka, Masaomi Nangaku

Published in: Clinical and Experimental Nephrology | Issue 6/2019

Login to get access

Abstract

Background

This study aims to describe the regional variance in prescriptions for chronic kidney disease (CKD) medications and to analyze regional characteristics to identify the sources of these differences by utilizing the National Database of Health Insurance Claims, which provides more than 95% of nationwide claim information for Japan.

Methods

Data regarding the total claimed amount for phosphate binders (PBs), erythropoiesis-stimulating agents (ESAs), carbonaceous adsorbents, and potassium-lowering agents in fiscal year 2015 were obtained. Correlation coefficients were calculated for the claimed amount of these drugs per CKD patient and social and medical variables, including the percentage of the population aged ≥ 65 years and the numbers of hospital beds and certified nephrologists. Subsequent multiple regression analysis was performed using explanatory factors affecting the amount of PB or ESA prescriptions per CKD patient.

Results

The total claimed amounts were 585,485,115 for PBs and 2,373,777 for ESAs. Variations in the claimed amount per CKD patient among 47 prefectures were 4.9-, 6.1-, 6.6-, and 6.0-fold for PBs, ESAs, carbonaceous adsorbents and potassium-lowering agents, respectively. The number of nephrologists per CKD patient was positively correlated with the prescribed amount for PBs and ESAs per CKD patient, and independently associated with the prescribed amount also in regression analysis.

Conclusion

Substantial regional variation in CKD-related drug prescriptions exists even within a uniform health care system. The number of certified nephrologists was associated with the prescribed amount for PBs and ESAs. Further studies are needed to clarify whether geographic distribution of certified nephrologist may affect clinical practice pattern.
Literature
1.
go back to reference Ikegami N, Yoo BK, Hashimoto H, Matsumoto M, Ogata H, Babazono A, et al. Japanese universal health coverage: evolution, achievements, and challenges. Lancet. 2011;378:1106–15.CrossRefPubMed Ikegami N, Yoo BK, Hashimoto H, Matsumoto M, Ogata H, Babazono A, et al. Japanese universal health coverage: evolution, achievements, and challenges. Lancet. 2011;378:1106–15.CrossRefPubMed
2.
go back to reference Ishikawa KB. Medical big data for research use: current status and related issues. Japan Med Assoc J. 2016;59:110–24.PubMedPubMedCentral Ishikawa KB. Medical big data for research use: current status and related issues. Japan Med Assoc J. 2016;59:110–24.PubMedPubMedCentral
3.
go back to reference Mues KE, Liede A, Liu J, Wetmore JB, Zaha R, Bradbury BD, et al. Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US. Clin Epidemiol. 2017;9:267–77.CrossRefPubMedPubMedCentral Mues KE, Liede A, Liu J, Wetmore JB, Zaha R, Bradbury BD, et al. Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US. Clin Epidemiol. 2017;9:267–77.CrossRefPubMedPubMedCentral
4.
go back to reference Yamasaki D, Tanabe M, Muraki Y, Kato G, Ohmagari N, Yagi T. The first report of Japanese antimicrobial use measured by national database based on health insurance claims data (2011–2013): comparison with sales data, and trend analysis stratified by antimicrobial category and age group. Infection. 2018;46:207–14.CrossRefPubMed Yamasaki D, Tanabe M, Muraki Y, Kato G, Ohmagari N, Yagi T. The first report of Japanese antimicrobial use measured by national database based on health insurance claims data (2011–2013): comparison with sales data, and trend analysis stratified by antimicrobial category and age group. Infection. 2018;46:207–14.CrossRefPubMed
6.
go back to reference Kamata Y, Minota S. Wide difference in biologics usage and expenditure for the treatment of patients with rheumatoid arthritis in each prefecture in Japan analyzed using “National Database of Health Insurance Claims and Specific Health Checkups of Japan”. Rheumatol Int. 2018;38:663–68.CrossRefPubMed Kamata Y, Minota S. Wide difference in biologics usage and expenditure for the treatment of patients with rheumatoid arthritis in each prefecture in Japan analyzed using “National Database of Health Insurance Claims and Specific Health Checkups of Japan”. Rheumatol Int. 2018;38:663–68.CrossRefPubMed
7.
go back to reference Jardine MJ, Kasiske B, Adu D, Alrukhaimi M, Ashuntantang GE, Basnet S. Closing the gap between evidence and practice in chronic kidney disease. Kidney Int Suppl. 2017;7:114–21.CrossRef Jardine MJ, Kasiske B, Adu D, Alrukhaimi M, Ashuntantang GE, Basnet S. Closing the gap between evidence and practice in chronic kidney disease. Kidney Int Suppl. 2017;7:114–21.CrossRef
8.
go back to reference Masakane I, Taniguchi M, Nakai S, Tsuchida K, Goto S, Wada A, et al. Annual dialysis data report 2015, JSDT renal data registry. Ren Replace Ther. 2018; 4:19.CrossRef Masakane I, Taniguchi M, Nakai S, Tsuchida K, Goto S, Wada A, et al. Annual dialysis data report 2015, JSDT renal data registry. Ren Replace Ther. 2018; 4:19.CrossRef
9.
go back to reference Chihara D, Ito H, Katanoda K, Shibata A, Matsuda T, Sobue T, et al. Incidence of myelodysplastic syndrome in Japan. J Epidemiol. 2014;24:469–73.CrossRefPubMed Chihara D, Ito H, Katanoda K, Shibata A, Matsuda T, Sobue T, et al. Incidence of myelodysplastic syndrome in Japan. J Epidemiol. 2014;24:469–73.CrossRefPubMed
10.
go back to reference Naito T, Ohtani H, Kobayashi K, Miyazaki M, Yamada K, Sugawara M. Current status of and regional differences in CKD management and medical cooperation in Japan: from the results of a nationwide questionnaire survey for primary care physicians [in Japanese]. Nihon Jinzo Gakkai Shi. 2013;55:1391–400.PubMed Naito T, Ohtani H, Kobayashi K, Miyazaki M, Yamada K, Sugawara M. Current status of and regional differences in CKD management and medical cooperation in Japan: from the results of a nationwide questionnaire survey for primary care physicians [in Japanese]. Nihon Jinzo Gakkai Shi. 2013;55:1391–400.PubMed
11.
go back to reference Nakamura S, Nakata H, Yoshihara F, Kamide K, Horio T, Nakahama H, et al. Effect of early nephrology referral on the initiation of hemodialysis and survival in patients with chronic kidney disease and cardiovascular diseases. Circ J. 2007;71:511–6.CrossRefPubMed Nakamura S, Nakata H, Yoshihara F, Kamide K, Horio T, Nakahama H, et al. Effect of early nephrology referral on the initiation of hemodialysis and survival in patients with chronic kidney disease and cardiovascular diseases. Circ J. 2007;71:511–6.CrossRefPubMed
12.
go back to reference Winkelmayer WC, Owen WF Jr, Levin R, Avorn J. A propensity analysis of late versus early nephrologist referral and mortality on dialysis. J Am Soc Nephrol. 2003;14:486–92.CrossRefPubMed Winkelmayer WC, Owen WF Jr, Levin R, Avorn J. A propensity analysis of late versus early nephrologist referral and mortality on dialysis. J Am Soc Nephrol. 2003;14:486–92.CrossRefPubMed
13.
go back to reference Kim DH, Kim M, Kim H, Kim YL, Kang SW, Yang CW, et al. Early referral to a nephrologist improved patient survival: prospective cohort study for end-stage renal disease in Korea. PLoS One. 2013;8:e55323.CrossRefPubMedPubMedCentral Kim DH, Kim M, Kim H, Kim YL, Kang SW, Yang CW, et al. Early referral to a nephrologist improved patient survival: prospective cohort study for end-stage renal disease in Korea. PLoS One. 2013;8:e55323.CrossRefPubMedPubMedCentral
14.
go back to reference Fischer MJ, Stroupe KT, Kaufman JS, O’Hare AM, Browning MM, Sohn MW, et al. Predialysis nephrology care and dialysis-related health outcomes among older adults initiating dialysis. BMC Nephrol. 2016;17:103.CrossRefPubMedPubMedCentral Fischer MJ, Stroupe KT, Kaufman JS, O’Hare AM, Browning MM, Sohn MW, et al. Predialysis nephrology care and dialysis-related health outcomes among older adults initiating dialysis. BMC Nephrol. 2016;17:103.CrossRefPubMedPubMedCentral
15.
go back to reference Baek SH, Ahn S, Lee SW, Park YS, Kim S, Na KY, et al. Outcomes of predialysis nephrology care in elderly patients beginning to undergo dialysis. PLoS One. 2015;10:e0128715.CrossRefPubMedPubMedCentral Baek SH, Ahn S, Lee SW, Park YS, Kim S, Na KY, et al. Outcomes of predialysis nephrology care in elderly patients beginning to undergo dialysis. PLoS One. 2015;10:e0128715.CrossRefPubMedPubMedCentral
16.
go back to reference Japanese Society of Nephrology. Essential points from evidence-based Clinical Practice Guidelines for Chronic Kidney Disease 2018. Clin Exp Nephrol. 2019;23:1–15.CrossRef Japanese Society of Nephrology. Essential points from evidence-based Clinical Practice Guidelines for Chronic Kidney Disease 2018. Clin Exp Nephrol. 2019;23:1–15.CrossRef
17.
go back to reference Furumatsu Y, Nagasawa Y, Hamano T, Iwatani H, Iio K, Shoji T, et al. Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan. Nephrol Dial Transplant. 2008;23:984–90.CrossRefPubMed Furumatsu Y, Nagasawa Y, Hamano T, Iwatani H, Iio K, Shoji T, et al. Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan. Nephrol Dial Transplant. 2008;23:984–90.CrossRefPubMed
18.
go back to reference Imasawa T, Nakazato T. Status of board-certified nephrologists of the Japanese Society of Nephrology among 47 prefectures [in Japanese]. Nihon Jinzo Gakkai Shi. 2010;52:1015–21.PubMed Imasawa T, Nakazato T. Status of board-certified nephrologists of the Japanese Society of Nephrology among 47 prefectures [in Japanese]. Nihon Jinzo Gakkai Shi. 2010;52:1015–21.PubMed
19.
go back to reference White H, Gillgrass L, Wood A, Peckham DG. Requirements and access needs of patients with chronic disease to their hospital electronic health record: results of a cross-sectional questionnaire survey. BMJ Open. 2016;6:e012257.CrossRefPubMedPubMedCentral White H, Gillgrass L, Wood A, Peckham DG. Requirements and access needs of patients with chronic disease to their hospital electronic health record: results of a cross-sectional questionnaire survey. BMJ Open. 2016;6:e012257.CrossRefPubMedPubMedCentral
20.
go back to reference Tsutsumi M, Shaku F, Ozone S, Sakamoto N, Maeno T. Reasons for the preference of clinic visits to self-medication by common cold patients in Japan. J Gen Fam Med. 2017;18:336–40.CrossRefPubMedPubMedCentral Tsutsumi M, Shaku F, Ozone S, Sakamoto N, Maeno T. Reasons for the preference of clinic visits to self-medication by common cold patients in Japan. J Gen Fam Med. 2017;18:336–40.CrossRefPubMedPubMedCentral
Metadata
Title
Regional variance in patterns of prescriptions for chronic kidney disease in Japan
Authors
Reiko Inoue
Hiroshi Nishi
Tetsuhiro Tanaka
Masaomi Nangaku
Publication date
01-06-2019
Publisher
Springer Singapore
Published in
Clinical and Experimental Nephrology / Issue 6/2019
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-019-01720-x

Other articles of this Issue 6/2019

Clinical and Experimental Nephrology 6/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.